Six out of ten people with type 2 diabetes had fatty liver in a new study from . Of these, only a small percentage had ...

A shocking new study shows a significant connection between type 2 diabetes and liver diseases, highlighting the increased ...

Discover a study where results suggest that while MASLD is common in patients with T2DM in primary care, advanced liver ...

"The POSITANO study shows that CAM2029 significantly reduces liver and liver cyst volume compared to placebo while showing improvements in symptoms as assessed by relevant patient ...

People with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) have significant differences in their blood compared ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is ...

The liver fibrosis market is entering a transformative phase, driven by greater awareness, improved diagnostic ...

The drug promotes lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis.

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND ...

Camurus announces positive results from POSITANO phase 2b study of octreotide SC depot in patients with symptomatic polycystic liver disease: Lund, Sweden Thursday, June 19, 2025, ...